SYSTEMIC LUPUS ERYTHEMATOSUS
Mycophenolate vs Cyclophosphamide for Severe Lupus Nephritis: nvestigators at the Center for Glomerular Diseases are participating in a new multi-national randomized trial comparing the efficacy and safefy of Mycophenolate mofetil (Cellcept) versus IV cyclophosphamide (cytoxan) in inducing response and maintaining remission in severe lupus nephritis
Rituximab for Proliferative Lupus Nephritis: Rituximab vs. placebo in patients treated with mycophenolate for diffuse proliferative lupus nephritis.
Completed Studies and Trials
An FDA sponsored study examined 140 SLE patients with active kidney disease randomized to mycophenolate mofetil (cellcept) versus monthly pulse IV cyclophosphamide. Patients receiving mycophenolate had a greater number of complete and partial remissions with greater tolerability than cyclophosphamide in an intention to treat analysis (Ginzler EM, Appel G et al. N Engl J Med. 2005 Nov 24;353(21):2219-28.)